Identification of Disulfidptosis-Related LncRNA Subtypes, Establishment of a Prognostic Signature, and Characterization of Immune Infiltration in Ovarian Cancer
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study introduces a novel seven-lncRNA signature for predicting ovarian cancer prognosis and guiding therapy. This disulfidptosis-related signature may improve patient outcomes and treatment strategies.
Area Of Science
- Oncology
- Molecular Biology
- Genetics
Background
- Ovarian Cancer (OC) presents a significant challenge due to its poor prognosis.
- Disulfidptosis, a cell death pathway induced by disulfide stress, offers a novel therapeutic target.
- Identifying prognostic biomarkers is crucial for improving OC patient management.
Purpose Of The Study
- To develop and validate a prognostic signature based on disulfidptosis-related long non-coding RNAs (lncRNAs) in OC.
- To explore the potential therapeutic implications of this signature.
- To enhance predictive accuracy using a nomogram integrating clinical factors.
Main Methods
- Utilized TCGA and GTEx data to construct a disulfidptosis-related lncRNA signature.
- Validated the model internally and externally using PCR.
- Employed Gene Set Enrichment Analysis (GSEA) for functional exploration.
- Assessed the tumor immune microenvironment using ESTIMATE, CIBERSORT, TIMER, and ssGSEA.
- Analyzed drug sensitivity in relation to the prognostic signature.
Main Results
- A seven-lncRNA signature (AL157871.2, HCP5, AC027348.1, AL109615.3, AL928654.1, LINC02585, AC011445.1) was established and validated.
- A nomogram integrating age, grade, stage, and risk score accurately predicted OC survival.
- The signature was linked to the Hedgehog signaling pathway and immune checkpoints (PD-1, PD-L1, CTLA4), suggesting potential for immunotherapy.
- Identified potential targeted therapies (AZD-2281, GDC-0449, imatinib, nilotinib) for different risk groups.
Conclusions
- The developed disulfidptosis-related lncRNA signature serves as a robust prognostic biomarker for OC.
- This signature can guide therapeutic strategies and predict treatment response in OC patients.
- The findings highlight the potential of targeting disulfidptosis for novel OC therapies.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
